Human disease
junctional epidermolysis bullosa, non-Herlitz type
Mondo defines it as: “Junctional epidermolysis bullosa, non-Herlitz (JEB-nH) is a subtype of junctional epidermolysis bullosa (JEB) characterized by the presence of skin and mucosal blistering, nail dystrophy or nail absence and enamel hypoplasia.”
6 disease groups in OMIA reach this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 2269 | Epidermolysis bullosa, junctionalis, LAMB3-related | OMIA's OMIM numbers | 2 | Drug |
62.4
|
| 1677 | Epidermolysis bullosa, junctionalis, LAMA3-related | OMIA's OMIM numbers | 3 | Drug |
60.4
|
| 1678 | Epidermolysis bullosa, junctionalis, LAMC2-related | OMIA's OMIM numbers | 3 | Drug |
59.3
|
| 1948 | Epidermolysis bullosa, junctionalis, ITGB4-related | OMIA's OMIM numbers | 2 | Target evidence |
52.2
|
| 342 | Epidermolysis bullosa, junctionalis | OMIA's OMIM numbers | 3 | Human disease |
15.0
|
| 340 | Epidermolysis bullosa | OMIA's OMIM numbers | 2 | Human disease |
12.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| LAMB3 | 0.80 | 135 |
| LAMA3 | 0.65 | 36 |
| LAMC2 | 0.62 | 22 |
| ITGB4 | 0.58 | 13 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
No drug has been tested for this disease.